Gov. Jack Markell's office says plans by pharmaceutical company AstraZeneca PLC to eliminate 550 jobs at its U.S. headquarters in Delaware is not part of a plan to pull out of the state altogether.
Spokesman Brian Selander tells WDEL-AM that the layoffs are instead a shift of emphasis by the company.
The termination of psychiatric laboratory research in Delaware represents about one-third of the company's research and development work force in the state, where future R&D efforts will focus on shepherding drugs through clinical trials and regulatory approval.
AstraZeneca says its facilities in Boston will see some growth as employees transfer from other sites.
Information from WDEL-AM: www.wdel.com